Sign in

You're signed outSign in or to get full access.

Bridget van Kralingen

Director at Schrodinger
Board

About Bridget van Kralingen

Bridget van Kralingen (age 61) joined Schrödinger’s board in March 2025 and is standing for election as a Class II director at the June 18, 2025 annual meeting. She is a Senior Partner and executive committee member at Motive Partners, and previously held multiple global senior leadership roles at IBM after earlier senior tenure at Deloitte; she holds a Master of Commerce (Industrial & Organisational Psychology), a B.Com, and an honours degree in commerce from South African universities . The board determined she is independent under Nasdaq rules; her current SDGR board tenure is since March 2025 .

Past Roles

OrganizationRoleTenureCommittees/Impact
IBMSenior Vice President; previously CEO/SVP IBM Global Markets; SVP Global Industries, Clients, Platforms & Blockchain; SVP Global Business Services; GM IBM North America; GM GBS EMEA; Global Managing Partner, Financial Services Sector2004–Nov 2022Led large-scale global client, platform and services businesses; enterprise software and technology solutions experience
Deloitte ConsultingManaging Partner, US Financial ServicesPre-2004 (prior to IBM)Financial services client leadership and consulting operations

External Roles

OrganizationRoleTenureNotes
Motive PartnersSenior Partner; Executive Committee memberNov 2022–presentPE firm focused on technology-enabled financial/business services
Teradyne, Inc.DirectorCurrentPublic company; automated test equipment/robotics; committee roles not disclosed here
The Travelers Companies, Inc.DirectorCurrentPublic insurance company; committee roles not disclosed here
Discovery LimitedDirectorCurrentSA-founded financial services; committee roles not disclosed here
Royal Bank of CanadaDirector (former)Jun 2011–Apr 2024Departed April 2024

Board Governance

  • Independence: The board determined all directors except CEO Ramy Farid and co-founder Richard A. Friesner are independent; van Kralingen is independent under Nasdaq rules .
  • Committees: Audit (Sender, Ginsberg, Lynton, Oberoi), Compensation (Sender, Ginsberg, Kapeller‑Libermann), Nominating/Governance (Lynton, Chodakewitz, Thornberry), Drug Discovery (Chodakewitz, Kapeller‑Libermann, Thornberry). No committee assignment for van Kralingen disclosed as of April 24, 2025 .
  • Board structure: Independent chair (Michael Lynton); no Lead Independent Director given independent chair; CEO and Chair roles separated .
  • Executive sessions: Independent directors meet at least twice annually .
  • Attendance: In 2024 the board met 5 times and all then-serving directors met ≥75% attendance of board and committee meetings; van Kralingen joined in 2025 so 2024 data not applicable .
  • Classified board: Directors serve staggered three-year terms; van Kralingen is a Class II nominee in 2025 .
  • Shareholder engagement on governance: 2024 director election support was 76–81% for Class I; investor concerns cited over classified board and multiple outside boards; the company states it reviews “over-boarding” and found directors’ time commitments sufficient .

Fixed Compensation (Non-Employee Director)

Component2024 Policy2025 Policy (effective Jan 1, 2025)
Board annual cash retainer (member)$45,000 $50,000
Board chair supplemental annual fee$40,000 $40,000
Audit Committee (member / chair add’l)$10,000 / $10,000 $10,000 / $10,000
Compensation Committee (member / chair add’l)$7,500 / $7,500 $7,500 / $7,500
Nominating & Governance (member / chair add’l)$5,000 / $5,000 $5,000 / $5,000
Drug Discovery (member / chair add’l)$7,500 / $7,500 $7,500 / $7,500

Notes:

  • 2024 non-employee director comp table does not include van Kralingen as she joined in 2025 .

Performance Compensation (Director Equity; Time-Based)

Grant Type2024 Policy2025 PolicyVesting
Initial option (upon appointment)Value $237,500 (cap ≤17,050 shrs) Value $252,500 (cap ≤25,480 shrs) 1/3 per year over 3 years, service-based
Initial RSU (upon appointment)Value $237,500 (cap ≤10,000 shrs) Value $252,500 (cap ≤15,190 shrs) 1/3 per year over 3 years, service-based
Annual option (at annual meeting)Value $118,750 (cap ≤8,550 shrs) Value $126,250 (cap ≤12,740 shrs) Vests on 12-month anniversary or next AGM, service-based
Annual RSU (at annual meeting)Value $118,750 (cap ≤5,000 shrs) Value $126,250 (cap ≤7,595 shrs) Vests on 12-month anniversary or next AGM, service-based
  • No director performance (PSU/TSR) metrics are used; all director equity is time-based per policy .
  • Options are granted at fair market value; specific option term for directors not separately stated in the policy excerpts; awards follow plan terms .

Other Directorships & Interlocks

CompanyCategoryPotential Interlock/Conflict
Teradyne, Inc.Tech hardware/roboticsNo SDGR-related transaction disclosed
The Travelers Companies, Inc.P&C insuranceNo SDGR-related transaction disclosed
Discovery LimitedFinancial servicesNo SDGR-related transaction disclosed
Royal Bank of Canada (former)BankingDeparted April 2024
  • SDGR’s related-person disclosure lists only Columbia/Friesner arrangements and Gates Foundation share exchange; no transactions involving van Kralingen or her affiliated entities are disclosed .

Expertise & Qualifications

  • Enterprise technology and software solutions leadership across IBM’s global markets, industries, platforms, and services businesses; deep financial services client expertise from IBM and Deloitte .
  • Board experience across multiple large-cap public companies (technology, insurance, financial services) .
  • Education: M.Com (Industrial & Organisational Psychology) University of South Africa; B.Com University of the Witwatersrand; honours degree in commerce University of Johannesburg .

Equity Ownership

HolderCommon Shares Beneficially Owned% of CommonNotes
Bridget van KralingenNo beneficial ownership reported as of April 1, 2025; newly appointed in March 2025 .

Ownership alignment policies

  • Director stock ownership guideline: 3.0x annual cash retainer; five-year phase-in for new directors .
  • Compliance status: As of April 21, 2025, all directors and executive officers met guidelines except Porges, Dugan, and van Kralingen (newly appointed) .
  • Hedging/pledging prohibitions: Hedging prohibited; pledging generally prohibited with limited exceptions. Only Friesner has a disclosed pledge; no pledges by van Kralingen disclosed .

Governance Assessment

Key findings

  • Independence and fresh perspective: Newly appointed independent director with deep enterprise software and financial services expertise; could strengthen board oversight of SDGR’s software go-to-market and partnerships .
  • Committee impact: No committee assignment disclosed yet; near-term influence will be at full board level until committee placement is made .
  • Time-commitment risk: Serves on three current public-company boards while holding a senior role at a private equity firm. Investors raised over-boarding concerns in 2024; SDGR states it reviews director commitments regularly and deems current commitments sufficient, but this remains a monitoring item for investors focused on director capacity and engagement .
  • Alignment and incentives: Director pay mix is cash + time-vested equity; 2025 policy increased retainers and equity values modestly, aligned with market. Ownership guidelines require 3x retainer; she is within the five-year compliance window as a new appointee .
  • Related-party risk: No related-party transactions involving van Kralingen disclosed; SDGR has formal related-person review procedures overseen by the Audit Committee .
  • Board/ESG governance: Independent chair; executive sessions; ongoing shareholder engagement with responsive changes (e.g., expanded use of performance-based equity for executives; active review of classified board topic); 98% say-on-pay support in 2024 indicates broad investor confidence in pay governance .

RED FLAGS to monitor

  • Potential over-boarding perception given multiple outside directorships and a senior PE role (company indicates review and sufficiency but investor thresholds vary) .
  • Classified board structure remains a recurring governance critique among some investors (company continues to review) .

Overall implication for investor confidence

  • Van Kralingen brings highly relevant software/commercial expertise and a strong board resume; independence is clear and no conflicts are disclosed, supporting governance quality. The key watch item is time-commitment optics given multi-board service; committee placement and attendance data in 2025–2026 will be important signals of board effectiveness .